We have tested the specificity and utility of more than 200 antibodies raised against 57 different histone modifications in Drosophila melanogaster, Caenorhabditis elegans and human cells. Although most antibodies performed well, more than 25% failed specificity tests by dot blot or western blot. Among specific antibodies, more than 20% failed in chromatin immunoprecipitation experiments. We advise rigorous testing of histone-modification antibodies before use, and we provide a website for posting new test results (http://compbio.med.harvard.edu/antibodies/). This December, we celebrate the 100 th anniversary of Albrecht Kossel's 1910 Nobel Prize in Physiology or Medicine, which was awarded in part for his discovery of histone proteins 1 . In 1964, soon after elucidation of the DNA-RNA-protein 'Central Dogma' , came strong experimental evidence that histones are acetylated and methylated after completion of the polypeptide chain, and that these histone modifications "affect the capacity of the histones to inhibit ribonucleic acid synthesis in vivo" 2 . This work foreshadowed a very active period since the early 1990s, which has brought an explosion of insight regarding how DNA is packaged into chromatin, the multitude of enzymes that modify key histone residues in eukaryotic cells, and how those marks are associated with diverse functional states of chromatin 3 .
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Key to these recent advances has been the availability of antibodies to dozens of specific post-translational modifications on histones, coupled with the advent of chromatin immunoprecipitation (ChIP), DNA microarrays (ChIP-chip) and highly parallel DNA sequencing (ChIP-seq). This combination of antibodies and technology has enabled investigators to determine the genomic distributions of histone modifications and to connect them with biological functions 3 . However, the reproducibility and biological relevance of histone-modification landscapes depends on the specificity and performance of the antibodies, most of which are now provided commercially. The validity of results could be affected by recognition of unmodified histones, nontarget modifications and nonhistone proteins. In addition, antibodies might be highly specific, but be ineffective ChIP reagents.
Here we set out to assess the quality of histone-modification antibodies by western blot, dot blot and ChIP-chip or ChIP-seq analysis.
RESULTS
As part of our activities in the NIH modENCODE 4 and Roadmap Reference Epigenome 5 initiatives, we performed three types of characterization on 246 antibodies directed against 3 unmodified histones and 57 distinct histone modifications (Supplementary Table 1 ). We used western blot analysis to test for cross-reactivity of the antibodies with unmodified histones or with nonhistone proteins in nuclear or whole-cell extracts. We used dot blots with a panel of modified peptides to test for cross-reactivity with other modifications. We also used ChIP-chip or ChIP-seq 6 to test the ability of the antibodies to reproducibly immunoprecipitate discrete DNA regions. The results are summarized below, with the details provided in Supplementary Table 1 .
Western blot analysis
For western blot analysis of samples from D. melanogaster and C. elegans, we electrophoresed a threefold dilution series of both total 9 2 VOLUME 18 NUMBER 1 JANUARY 2011 nature structural & molecular biology r e s o u r c e nuclear extract from wild-type embryos and unmodified recombinant histone on an SDS polyacrylamide gel, using an amount of recombinant histone that was comparable to the corresponding histone level in the nuclear extract (Fig. 1a) . We set the following criteria for an antibody to 'pass': the histone band constituted at least 50% of the total nuclear signal; was at least ten-fold more intense than any other single nuclear band; and was at least ten-fold more intense than recombinant, unmodified histone. By these criteria, 80 of the 127 histone-modification antibodies tested (63%) passed, whereas 33 (26%) failed, and 14 (11%) produced no signal (Fig. 1b,c) . For western blots of human samples, we used whole-cell extract instead of nuclear extract. This resulted in a higher frequency of crossreacting bands, many of which are likely to be irrelevant to assays performed on nuclear proteins. Therefore, we did not classify these as 'pass' or 'fail' but described their behavior as shown in Figure 1d .
Dot blot analysis
Dot blots were performed using a matrix of 43 peptides (Fig. 2a) or on one of the arrays of peptides shown in Supplementary  Figure 1a ,b. For an antibody to pass, we required that at least 75% of the total signal be specific to the cognate peptide. According to this criterion, 109 of the 149 antibodies tested (73%) passed, of which 56% (61/109) showed 100% specificity. By contrast, 20 (13%) of the antibodies produced signal on the dot blot but did not meet our specificity criterion, 16 (11%) yielded no signal and 4 (3%) had low signal (Fig. 2b) . A particularly dangerous class of failure was defined by four antibodies (3%) that showed 100% specificity, but for the wrong peptide (Supplementary Table 1 ).
ChIP-chip and ChIP-seq analysis
We performed ChIP-chip or ChIP-seq experiments using 147 of the histone-modification antibodies, and we judged them to have passed if they achieved a correlation of more than 0.8 on any pair of ChIPs r e s o u r c e performed from independent preparations matched for stage, cell type or biological tissue (Fig. 3a) . This criterion evaluates only the effectiveness of the antibody to generate reproducible ChIP results, and it does not measure whether the resulting distributions are biologically accurate. In the case of well-studied modifications, we were able to confirm that the signal conformed to previously established patterns: for example, anti-H3K4me3 (histone H3 trimethyl lysine 4) precipitating chromatin near gene promoters 3 . In all, 115 of the 147 antibodies tested by ChIP (78%) passed, and 32 (22%) failed ( Fig. 3b and Supplementary Table 1) . Of the failures, 23 were marketed as ChIP-grade.
DISCUSSION
Our results show that most commercially available histonemodification antibodies perform well, but that at least 25% have substantial problems of specificity or utility, suggesting that users should independently test purchased antibodies. Failure in one assay does not necessarily predict failure in another, indicating that antibodies should be tested in multiple assays regardless of initial success or failure in a given assay. Manufacturers often provide peptide blot data, but assessment of cross-reactivity with nonhistone proteins is usually restricted to one species, and the data presented are often based on lots that are no longer available for purchase. Substantial lot-to-lot variation (Supplementary Table 1 ) mandates that lots be tested separately using extracts from the species under study. Development of monoclonal antibodies to histone modifications may alleviate many of these concerns 7 . The high rate of specificity problems raises concerns about the validity of ChIP data that have been generated and published without independent characterization. To help to address issues of antibody quality in the community, we have developed an Antibody Validation Database website (http:// compbio.med.harvard.edu/antibodies/) that allows researchers to post their assay results. This will provide up-to-date validation information, including tests of lot-to-lot variability. The website currently contains all histone-modification validation data described in this paper as well as data for other chromosomal proteins tested in the modENCODE project. The database can be searched by the modification or protein name, and it lists antibody details (source, catalog number, lot number and so on), links to the validation data including images, and other information such as the species and the laboratory in which testing was performed. Researchers who publish data generated using histone-modification antibodies are encouraged to upload their validation information to this site.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
ONLINE METhODS
In addition to the websites below, all information about the antibodies is also listed at http://compbio.med.harvard.edu/antibodies/.
C. elegans nuclear extracts and western blotting. C. elegans embryos, obtained by dissolving adult worms with bleach, were washed and dounce-homogenized 50 times using a tight pestle. Nuclei were collected by centrifugation and sonicated twice for 30 min each time using a Branson sonicator to prepare extract. Samples in sample buffer were boiled, and three-fold dilution series of both nuclear extract and recombinant histone (Active Motif) were electrophoresed on a 12.5% (w/v) SDS-polyacrylamide gel. The gel was stained with Coomassie blue to verify that approximately equal levels of recombinant histone and the corresponding histone were loaded. Samples were transferred to a nitrocellulose membrane. The membrane was blocked in nonfat milk, incubated with primary antibody, washed, incubated with secondary antibody, washed and developed with ECL (Pierce). Western blot images are available at http://www.modencode.org/docs/hmav.html.
D. melanogaster nuclear extracts and western blotting. D. melanogaster embryo nuclear extracts were prepared 8 . Three different dilutions of nuclear extract and recombinant histone (expressed in E. coli) were separated on an SDSpolyacrylamide gel. Western blot analysis was performed as described above.
Human western blotting. Whole cell extracts (WCE) were made from HCT116 cells. Samples were run on precast 4-20% gels and transferred to membrane. Western blot analysis was performed as described above. Detailed protocols and images of all blots can be downloaded from the San Diego Epigenome Center website: http://epigenome.ucsd.edu/.
Dot blots (group 1)
. Single-modification peptides were obtained from Abcam and Active Motif. The purity of peptides was 70-95%. Peptides were spotted onto nitrocellulose membrane in the pattern shown in Figure 2a . The membrane was blocked in nonfat milk, incubated with primary antibody, washed, incubated with secondary antibody, washed, developed with ECL (Pierce), exposed in an imager and analyzed. Illuminated spots were encircled and quantified. Percent specificity is relative to total intensity of all illuminated modified-peptide spots normalized to background. Detailed protocols and images of all blots can be downloaded from the San Diego Epigenome Center website: http://epigenome.ucsd.edu/.
Dot blots (group 2)
. Slot/dot blot analysis was carried out as described 9 using nitrocellulose membrane and peptide (Diagenode) amounts from 100 to 3 pmol. Diagenode states that the purity of peptides is >70%. The intensities of the bands were analyzed by Image J, and percent specificity was calculated relative to total intensity of all spots. For peptide array, see Supplementary Figure 1a .
Dot blots (group 3). PVDF membranes (0.45 µm pore size) were prewashed in 100% methanol, rinsed three times in PBS and spotted with 100, 25 and 10 pmol of each peptide (Diagenode) in a 28-peptide matrix (Supplementary Fig. 1b) .
The membrane was allowed to dry, washed in 100% methanol, rinsed three times in PBS, blocked in 5% (w/v) milk for 3 h and then incubated with antibody.
C. elegans ChIP-chip. ChIP-chip experiments were performed as described for early embryos 10 and L3 worms 11 .
D. melanogaster ChIP-chip. ChIP experiments were performed as described 12 , with some changes. S2 Drosophila cultured cells were fixed in formaldehyde
